Add Yahoo as a preferred source to see more of our stories on Google. Boston Scientific’s Watchman FLX Pro device, the latest version of its left atrial appendage closure system, was approved by the ...

Boston Scientific (NYSE:BSX) today shared new clinical findings supporting its wide-ranging electrophysiology (EP) portfolio.

Add Yahoo as a preferred source to see more of our stories on Google. Boston Scientific has shared a duo of positive data readouts from two separate trials evaluating its Watchman FLX left atrial ...

MARLBOROUGH, Mass. and NEW ORLEANS, March 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary ...

The U.S. FDA expanded the approval for use of Boston Scientific Corp.’s Watchman Flx and Watchman Flx Pro left atrial appendage closure (LAAC) devices to include post-ablation patients, bringing good ...

Boston Scientific, one of the top 100 medical device companies, reported positive clinical trial results over the weekend that could support FDA label expansion of its Watchman FLX device. Boston ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

The latest-generation WATCHMAN FLX™ Pro LAAC Device was approved in the U.S. in 2023 and is currently being studied in several clinical trials, including the SIMPLAAFY randomized controlled trial, ...

Boston Scientific has shared a duo of positive data readouts from two separate trials evaluating its Watchman FLX left atrial appendage closure (LAAC) device in non-valvular atrial fibrillation (AF) ...

Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial ...